Mark Goldsmith
Amministratore Delegato presso REVOLUTION MEDICINES, INC.
Patrimonio netto: 30 M $ in data 30/04/2024
Profilo
Mark A.
Goldsmith was the founder of Cogentus Pharmaceuticals, Inc. (founded in 2006) and Revolution Medicines, Inc. (founded in 2014), where he holds the titles of Chairman, President & Chief Executive Officer.
He is currently working as a Director at Nura Bio, Inc. Dr. Goldsmith's former positions include President, Chief Executive Officer & Director at Global Blood Therapeutics, Inc. (2012-2014), Chairman at Nurix Therapeutics, Inc. (2012-2016), Chairman at Constellation Pharmaceuticals, Inc. (2009-2021), Director at Igenica Biotherapeutics, Inc., Assistant Director at The J.
David Gladstone Institutes, Senior Vice President at Genencor International, Inc., Member at Roche Group, and Senior Executive-in-Residence at Prospect Venture Partners.
He also worked as a Partner at Third Rock Ventures LLC (2012-2015).
Dr. Goldsmith's education includes an undergraduate degree from Princeton University and a doctorate degree from The University of California, San Francisco.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 10/04/2024 | 841 274 ( 0.51% ) | 30 M $ | 30/04/2024 |
Posizioni attive di Mark Goldsmith
| Società | Posizione | Inizio |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Amministratore Delegato | 01/11/2014 |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Mark Goldsmith
| Società | Posizione | Fine |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Amministratore Delegato | 01/03/2012 |
| NURIX THERAPEUTICS, INC. | Amministratore Delegato | 18/09/2014 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investitore di Private Equity | 01/01/2015 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Amministratore Delegato | 17/06/2014 |
Cogentus Pharmaceuticals, Inc.
 Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cogentus Pharmaceuticals, Inc. develops pharmaceutical products. Its investors include The Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. The company was founded by Mark A. Goldsmith in 2006 and is headquartered in Menlo Park, CA | Amministratore Delegato | 18/12/2009 |
Formazione di Mark Goldsmith
| Princeton University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NURIX THERAPEUTICS, INC. | Health Technology |
| REVOLUTION MEDICINES, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
Cogentus Pharmaceuticals, Inc.
Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cogentus Pharmaceuticals, Inc. develops pharmaceutical products. Its investors include The Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. The company was founded by Mark A. Goldsmith in 2006 and is headquartered in Menlo Park, CA | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Finance |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
The J. David Gladstone Institutes
 The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | Commercial Services |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
- Borsa valori
- Insiders
- Mark Goldsmith
